{"id":2225,"date":"2026-10-08T03:56:36","date_gmt":"2026-10-08T03:56:36","guid":{"rendered":"https:\/\/health.myinstants39.com\/zydus-launches-in-u-s-msn-labs-generic-of-bayers-pah-drug\/"},"modified":"2026-10-08T03:56:36","modified_gmt":"2026-10-08T03:56:36","slug":"zydus-launches-in-u-s-msn-labs-generic-of-bayers-pah-drug","status":"publish","type":"post","link":"https:\/\/healthcare.hibisports.com\/?p=2225","title":{"rendered":"Zydus launches in U.S. MSN Labs generic of Bayer\u2019s PAH drug"},"content":{"rendered":"<div class=\"schemaDiv\" id=\"schemaDiv\">\n<p>Zydus Lifesciences has launched in the U.S. market Riociguat tablets, in  multiple strengths, developed and manufactured by MSN Laboratories.<\/p>\n<p>The two companies are the first to launch the product, which is a generic version of Bayer\u2019s Adempas. Approved by the U.S. Food and Drug Administration as a generic equivalent of Adempas tablets, in all five strengths, Riociguat tablets are indicated for treatment of persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable CTEPH; and pulmonary arterial hypertension (PAH).<\/p>\n<p>\u201cBeing first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension. It reflects the strength of our complex-generics pipeline, our ability to execute day-one launches in specialty categories and the strength of our partnerships that complement our commercial reach in the U.S.\u201d Zydus Lifesciences Managing Director Sharvil Patel said in a release on Monday.<\/p>\n<div class=\"also-read print-hide\" data-ga-label=\"AlsoReadArticle\">\n<div class=\"element\">\n<div class=\"title\">\n\t\t\t\t\t\t\t\t\t\tZydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million<\/div>\n<div class=\"picture\"><img decoding=\"async\" src=\"https:\/\/th-i.thgim.com\/public\/incoming\/ct2phu\/article70976817.ece\/alternates\/SQUARE_1200\/iStock-1354172444.jpg\" data-src-template=\"https:\/\/th-i.thgim.com\/public\/incoming\/ct2phu\/article70976817.ece\/alternates\/SQUARE_80\/iStock-1354172444.jpg\" data-original=\"https:\/\/www.thehindu.com\/theme\/images\/th-online\/1x1_spacer.png\" alt=\"\" data-device-variant=\"SQUARE~SQUARE~SQUARE~SQUARE\" class=\"media-object lazy adaptive placeholder lazy\" width=\"100%\" height=\"100%\"><\/div>\n<\/div>\n<\/div>\n<p>MSN Laboratories founder and CMD MSN Reddy said \u201cRiociguat is a technically demanding molecule and bringing the first generic to the U.S. demonstrates the depth of MSN\u2019s integrated API and formulation R&amp;D and the scale of our manufacturing. Together with Zydus\u2019 established U.S. commercial platform, we are confident of delivering consistent, high-quality supply of this important therapy.\u201d<\/p>\n<div class=\"also-read print-hide\" data-ga-label=\"AlsoReadArticle\">\n<div class=\"element\">\n<div class=\"title\">\n\t\t\t\t\t\t\t\t\t\tZydus secures U.S. FDA nod for scurvy injection generic<\/div>\n<div class=\"picture\"><img decoding=\"async\" src=\"https:\/\/th-i.thgim.com\/public\/incoming\/qephbm\/article71374779.ece\/alternates\/SQUARE_1200\/IMG_Zydus_Lifesciences_2_1_A9CQHO3E.jpg\" data-src-template=\"https:\/\/th-i.thgim.com\/public\/incoming\/qephbm\/article71374779.ece\/alternates\/SQUARE_80\/IMG_Zydus_Lifesciences_2_1_A9CQHO3E.jpg\" data-original=\"https:\/\/www.thehindu.com\/theme\/images\/th-online\/1x1_spacer.png\" alt=\"\" data-device-variant=\"SQUARE~SQUARE~SQUARE~SQUARE\" class=\"media-object lazy adaptive placeholder lazy\" width=\"100%\" height=\"100%\"><\/div>\n<\/div>\n<\/div>\n<p>Thus far, Riociguat was available in the U.S. only as the branded product. Sales of drug are not reported by IQVIA. According to Bayer\u2019s annual report 2025, the global sales of Adempas were around Euro 745 million (approximately $850 million) in 2025, Zydus said.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The two companies are the first to launch the product, which is a generic version of Bayer\u2019s Adempas.<\/p>\n","protected":false},"author":1,"featured_media":2633,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-2225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/posts\/2225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2225"}],"version-history":[{"count":0,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/posts\/2225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=\/wp\/v2\/media\/2633"}],"wp:attachment":[{"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthcare.hibisports.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}